HomepagePTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Vorige slotkoers
$Â 0,095
Jaar-range
$Â 0,087 - $Â 0,11
Beurswaarde
68,91Â bln. IDR
Gem. volume
62,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
IDX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 7,91Â bln. | 7,16% |
Bedrijfskosten | 2,29Â bln. | 15,55% |
Netto inkomsten | 573,28Â mld. | 6,97% |
Netto winstmarge | 7,25 | -0,14% |
Winst per aandeel | 12,41 | 7,73% |
EBITDA | 874,81Â mld. | 1,14% |
Effectief belastingtarief | 23,01% | — |
Balans
Totale activa
Totale passiva
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 4,32Â bln. | 45,45% |
Totale activa | 28,75Â bln. | 5,78% |
Totale passiva | 4,84Â bln. | 0,67% |
Totaal aandelenvermogen | 23,91 bln. | — |
Uitstaande aandelen | 46,15 mld. | — |
Koers-boekwaardeverhouding | 0,00 | — |
Rendement op activa | 6,15% | — |
Rendement op kapitaal | 7,16% | — |
Kasstroom
Nettomutatie in liquide middelen
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 573,28Â mld. | 6,97% |
Operationele kasstroom | 1,16Â bln. | 22,56% |
Kasstroom uit beleggingen | -176,64Â mld. | 33,78% |
Kasstroom uit financiering | -421,11Â mld. | 51,91% |
Nettomutatie in liquide middelen | 481,86Â mld. | 1.978,42% |
Vrije kasstroom | 752,00Â mld. | 13,84% |
Over
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Opgericht
10 sep 1966
Website
Werknemers
12.924